Kevin Oei
Overview
Explore the profile of Kevin Oei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yarava A, Marshall C, Reichert D, Ye A, Khanal P, Robbins S, et al.
J Clin Transl Sci
. 2024 Dec;
8(1):e200.
PMID: 39655012
Introduction: In response to the COVID-19 pandemic, we rapidly implemented a plasma coordination center, within two months, to support transfusion for two outpatient randomized controlled trials. The center design was...
2.
Park H, Yin A, Barranta C, Lee J, Caputo C, Sachithanandham J, et al.
JCI Insight
. 2024 Mar;
9(8.
PMID: 38483534
BACKGROUNDCOVID-19 convalescent plasma (CCP) virus-specific antibody levels that translate into recipient posttransfusion antibody levels sufficient to prevent disease progression are not defined.METHODSThis secondary analysis correlated donor and recipient antibody levels...
3.
Huaman M, Raval J, Paxton J, Mosnaim G, Patel B, Anjan S, et al.
Transfusion
. 2023 Aug;
63(9):1639-1648.
PMID: 37534607
Background: COVID-19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS-CoV-2 infection. We assessed the safety of outpatient CCP transfusions administered during...
4.
Park H, Yin A, Barranta C, Lee J, Caputo C, Sachithanandham J, et al.
medRxiv
. 2023 May;
PMID: 37131659
Background: The COVID-19 convalescent plasma (CCP) viral specific antibody levels that translate into recipient post-transfusion antibody levels sufficient to prevent disease progression is not defined. Methods: This secondary analysis correlated...
5.
Sullivan D, Gebo K, Shoham S, Bloch E, Lau B, Shenoy A, et al.
N Engl J Med
. 2022 Mar;
386(18):1700-1711.
PMID: 35353960
Background: Polyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients with recent-onset...
6.
Sullivan D, Gebo K, Shoham S, Bloch E, Lau B, Shenoy A, et al.
medRxiv
. 2022 Jan;
PMID: 34981068
Background: The efficacy of polyclonal high titer convalescent plasma to prevent serious complications of COVID-19 in outpatients with recent onset of illness is uncertain. Methods: This multicenter, double-blind randomized controlled...